Becton Dickinson and Co (NYSE:BDX) Holdings Boosted by Homrich & Berg

Homrich & Berg boosted its position in shares of Becton Dickinson and Co (NYSE:BDX) by 5.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,801 shares of the medical instruments supplier’s stock after purchasing an additional 156 shares during the period. Homrich & Berg’s holdings in Becton Dickinson and were worth $709,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bath Savings Trust Co raised its position in Becton Dickinson and by 12.5% in the second quarter. Bath Savings Trust Co now owns 27,899 shares of the medical instruments supplier’s stock valued at $7,031,000 after purchasing an additional 3,107 shares during the period. Thomasville National Bank grew its stake in shares of Becton Dickinson and by 5.3% in the second quarter. Thomasville National Bank now owns 1,667 shares of the medical instruments supplier’s stock valued at $420,000 after buying an additional 84 shares in the last quarter. Baystate Wealth Management LLC grew its stake in shares of Becton Dickinson and by 39.0% in the second quarter. Baystate Wealth Management LLC now owns 449 shares of the medical instruments supplier’s stock valued at $114,000 after buying an additional 126 shares in the last quarter. Private Asset Management Inc. grew its stake in shares of Becton Dickinson and by 2.0% in the second quarter. Private Asset Management Inc. now owns 2,532 shares of the medical instruments supplier’s stock valued at $638,000 after buying an additional 50 shares in the last quarter. Finally, Summit Financial Group Inc. acquired a new stake in shares of Becton Dickinson and in the second quarter valued at $208,000. Hedge funds and other institutional investors own 84.52% of the company’s stock.

NYSE BDX traded up $3.29 during trading on Wednesday, reaching $245.65. 52,351 shares of the company’s stock were exchanged, compared to its average volume of 1,172,876. The stock has a market cap of $66.08 billion, a P/E ratio of 21.02, a price-to-earnings-growth ratio of 1.72 and a beta of 1.09. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.73 and a current ratio of 1.19. The company has a 50 day moving average price of $251.34 and a two-hundred day moving average price of $247.15. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $264.74.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.30 by $0.01. The company had revenue of $4.58 billion during the quarter, compared to the consensus estimate of $4.57 billion. Becton Dickinson and had a return on equity of 15.51% and a net margin of 6.84%. Becton Dickinson and’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the previous year, the business earned $2.93 EPS. Research analysts forecast that Becton Dickinson and Co will post 12.57 EPS for the current fiscal year.

A number of brokerages have recently weighed in on BDX. ValuEngine cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. KeyCorp reaffirmed an “overweight” rating and issued a $256.00 price objective (down from $262.00) on shares of Becton Dickinson and in a research note on Wednesday. Piper Jaffray Companies dropped their price objective on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Morgan Stanley lifted their price objective on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 16th. Finally, Wells Fargo & Co dropped their price objective on Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Five equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $265.55.

In other news, SVP Charles R. Bodner sold 1,514 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $260.08, for a total value of $393,761.12. Following the completion of the sale, the senior vice president now directly owns 5,180 shares of the company’s stock, valued at approximately $1,347,214.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vincent A. Forlenza sold 11,532 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $260.38, for a total value of $3,002,702.16. Following the completion of the sale, the chief executive officer now directly owns 218,671 shares of the company’s stock, valued at $56,937,554.98. The disclosure for this sale can be found here. Insiders sold a total of 32,174 shares of company stock valued at $8,354,013 over the last three months. Company insiders own 0.12% of the company’s stock.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: What Are Cryptocurrencies?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.